Use of human monoclonal antibodies to treat Chikungunya virus infection

Journal of Infectious Diseases

Volumn 207, Issue 2, 2013, Pages 319-322

  Fric, Jan ^a   Bertin Maghit, Sébastien ^a   Wang, Cheng I ^a   Nardin, Alessandra ^a   Warter, Lucile ^a  

^a AGENCY FOR SCIENCE   (Singapore)

Author keywords

Chikungunya virus; in vivo; monoclonal antibodies; prophylactic; protection; therapeutic

Indexed keywords

IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 5F10; MONOCLONAL ANTIBODY 8B10; UNCLASSIFIED DRUG;

ANTIBODY ISOLATION; ARTICLE; CHIKUNGUNYA; CHIKUNGUNYA ALPHAVIRUS; DRUG EFFICACY; FEVER; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; TROPICAL DISEASE; VIRAL CLEARANCE; VIRUS NEUTRALIZATION;

ALPHAVIRUS INFECTIONS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; CHIKUNGUNYA VIRUS; DISEASE MODELS, ANIMAL; HUMANS; MICE; TREATMENT OUTCOME;

EID: 84871745796     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis674     Document Type: Article

References (14)

1. Pialoux G, Gauzere BA, Jaureguiberry S, Strobel M. Chikungunya, an epidemic arbovirosis. Lancet Infect Dis 2007; 7:319-27.
2. Borgherini G, Poubeau P, Jossaume A, et al. Persistent arthralgia associated with chikungunya virus: a study of 88 adult patients on reunion island. Clin Infect Dis 2008; 47:469-75.
3. Marini F, Caputo B, Pombi M, Tarsitani G, della TA. Study of Aedes albopictus dispersal in Rome, Italy, using sticky traps in mark-release- recapture experiments. Med Vet Entomol 2010; 24:361-8.
4. Farajollahi A, Nelder MP. Changes in Aedes albopictus (Diptera: Culi-cidae) populations in New Jersey and implications for arbovirus transmission. J Med Entomol 2009; 46:1220-4.
5. Chow A, Her Z, Ong EK, et al. Persistent arthralgia induced by Chi-kungunya virus infection is associated with interleukin-6 and granulo-cyte macrophage colony-stimulating factor. J Infect Dis 2011; 203:149-57.
6. Josseran L, Paquet C, Zehgnoun A, et al. Chikungunya disease outbreak, Reunion Island. Emerg Infect Dis 2006; 12:1994-5.
7. de LX, Ninove L, Charrel RN. Antiviral treatment of chikungunya virus infection. Infect Disord Drug Targets 2009; 9:101-4.
8. Couderc T, Khandoudi N, Grandadam M, et al. Prophylaxis and therapy for Chikungunya virus infection. J Infect Dis 2009; 200: 516-23.
9. Warter L, Lee CY, Thiagarajan R, et al. Chikungunya virus envelope-specific human monoclonal antibodies with broad neutralization potency. J Immunol 2011; 186:3258-64.
10. Lee CY, Kam YW, Fric J, et al. Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants. PLoS Pathog 2011; 7:e1002390.
11. Grob P, Schijns VE, van den Broek MF, Cox SP, Ackermann M, Suter M. Role of the individual interferon systems and specific immunity in mice in controlling systemic dissemination of attenuated pseudorabies virus infection. J Virol 1999; 73:4748-54.
12. Xiao X, Zhu Z, Dankmeyer JL, et al. Human anti-plague monoclonal antibodies protect mice from Yersinia pestis in a bubonic plague model. PLoS One 2010; 5:e13047.
13. Albrecht MT, Li H, Williamson ED, et al. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax. Infect Immun 2007; 75:5425-33.
14. Holland J, Spindler K, Horodyski F, Grabau E, Nichol S, Vande Pol S. Rapid evolution of RNA genomes. Science 1982; 215:1577-85.